Overview

Conference: October 24-25 | In-Person

In an ever-evolving healthcare landscape, real-world evidence (RWE) has emerged as a pivotal tool for shaping regulatory and reimbursement decisions. Traditionally associated with post-market safety monitoring, RWE now plays a critical role throughout the entire product development lifecycle. It enables real-time data analysis to enhance our understanding of diseases, refine treatment approaches, and substantiate coverage decisions.

DIA’s Real-World Evidence Conference is designed to delve into the latest advancements and innovative applications of RWE. From data standards, new regulatory guidances, and advanced approaches for noninterventional studies to the role of RWD in clinical trial diversity, this conference will provide participants with cutting-edge insights into how RWE is transforming drug development and regulatory practices. By exploring new methodologies, technological advancements, and practical case studies, the event will equip attendees with the knowledge and tools necessary to leverage RWE effectively and drive forward healthcare decision-making. Don’t miss this opportunity to stay ahead in the field and harness RWE’s full potential to impact patient outcomes and policy.

Need Approval in Order to Attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Download Letter

Participant Testimonials

DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees. – Nicholaas Honig, JD, Senior Regulatory Counsel, Aetion

Great meeting. Very strong content. Was a really efficient way for me to catch up on RWD/E happenings over the past year! – Meredith Zozus, PhD, Professor; Division Chief and Director, Clinical Research Informatics, University of Texas Health Science Center

Featured

Want to learn more about Real-World Evidence Conference? You've come to the right site!

Check out the great content lined up for DIA'sn Real-World Evidence Conference.

Program Chair Welcome Video

Who should attend?

Conference Designed For:
- Academia
- Clinical Research
- Data analytics
- Epidemiology
- Health Economics and Outcomes Research
- Pharmacovigilance
- Policy
- Real-World Evidence
- Real-World Data
- Regulatory Science
- Technology development

Learning objectives

Upon completion, learners should be able to:
- Identify new key milestones and significant advancements in real-world evidence (RWE) since last year
- Determine how RWE is used across different stages of drug development
- Identify advanced methodological approaches for generating RWE, including causal methods, negative control outcome studies, and sensitivity analyses, to improve the design and validity of non-interventional studies
- Evaluate the latest technological innovations and operational strategies, such as AI-enabled data abstraction and data linkage methods, to enhance the quality and efficiency of RWE generation
- Discuss how to leverage RWE to address health equity and improve diversity in drug development
- Examine international regulatory perspectives and practical challenges in applying RWE
- Assess the role of artificial intelligence in transforming clinical study designs, optimizing patient selection, and shaping policy frameworks to integrate AI with RWE effectively

Program Committee

David Martin, MD, MPH Vice President, Head, PCO Center of Excellence
Novartis, United States
Jaclyn Bosco, PhD, MPH, FISPE Vice President, Global Head of Epidemiology & Database Studies
IQVIA, United States
John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA, United States
Diane Gubernot, DrPH, MPH Epidemiologist
US FDA, United States
Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
Duke-Robert J. Margolis, MD, Center for Health Policy, United States
Camille Jackson Director, Regulatory Policy; Legal and Regulatory
Flatiron Health , United States
Charles Lee, MBA, MS Executive Regulatory Science Director
AstraZeneca, United States
SARAH K Martin, PhD, MS Senior Director - Global Regulatory Policy (Oncology)
Eli Lilly & Co., United States
Brittany Avin McKelvey, PhD Director, Regualtory Affairs
Friends of Cancer Research, United States
Keri Monda, PhD, MS Executive Director, Center for Observational Research
Amgen, United States
Representative Invited DIA, United States
Representative Invited DIA, United States